Cargando…

Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status

Following the success of cancer immunotherapy using large molecules against immune checkpoint inhibitors, the concept of using small molecules to interfere with intracellular negative regulators of anti-tumor immune responses has emerged in recent years. The main targets for small molecule drugs cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlicher, Lisa, Green, Luke G., Romagnani, Andrea, Renner, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644399/ https://www.ncbi.nlm.nih.gov/pubmed/38022587 http://dx.doi.org/10.3389/fimmu.2023.1297175

Ejemplares similares

Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status
por: Beeraka, Narasimha M., et al.
Publicado: (2020)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Lymphoma Immunotherapy: Current Status
por: Zappasodi, Roberta, et al.
Publicado: (2015)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

Current Status and Future Directions of Bacteria-Based Immunotherapy
por: Tang, Quan, et al.
Publicado: (2022)

Small Molecule-directed Immunotherapy against Recurrent Infection by Mycobacterium tuberculosis
por: Bhattacharya, Debapriya, et al.
Publicado: (2014)

Immunotherapy for B-Cell Lymphoma: Current Status and Prospective Advances
por: Hollander, Nurit
Publicado: (2012)

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: Current Status and Future Prospects
por: Singh, Om Prakash, et al.
Publicado: (2014)

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions
por: Wang, Mingming, et al.
Publicado: (2023)

Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S
por: Theron, Michel, et al.
Publicado: (2017)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

Current Immunotherapies for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2021)

Biomarkers for immunotherapy in esophageal cancer
por: Wang, Xuelian, et al.
Publicado: (2023)

Small Molecule NF-κB Inhibitors as Immune Potentiators for Enhancement of Vaccine Adjuvants
por: Moser, Brittany A., et al.
Publicado: (2020)

Immunotherapy for Glioblastoma: Current Progress and Challenges
por: Yu, Miranda W., et al.
Publicado: (2021)

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
por: Liang, Shuai, et al.
Publicado: (2023)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
por: Sasikumar, Pottayil G., et al.
Publicado: (2022)

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Research into the characteristic molecules significantly affecting liver cancer immunotherapy
por: Chen, Junhong, et al.
Publicado: (2023)

Erratum: Immunotherapy for Glioblastoma: Current Progress and Challenges
Publicado: (2021)

Clinical cancer immunotherapy: Current progress and prospects
por: Liu, Chenglong, et al.
Publicado: (2022)

Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
por: Teng, Chubei, et al.
Publicado: (2022)

Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4
por: Martín Monreal, María Teresa, et al.
Publicado: (2021)

Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling
por: Hrdinka, Matous, et al.
Publicado: (2018)

Current Advances in γδ T Cell-Based Tumor Immunotherapy
por: Lo Presti, Elena, et al.
Publicado: (2017)

Immunotherapy in Lung Cancer: Current Landscape and Future Directions
por: Mamdani, Hirva, et al.
Publicado: (2022)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

A close look at current γδ T-cell immunotherapy
por: Ma, Ling, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021)

Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical
por: Kong, Yichao, et al.
Publicado: (2023)

Hypersensitivity reactions to small molecule drugs
por: Han, Jiayin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rjajjffh7quvecr1bh2g8h80vi